Japan to improve blood products independence through merger of plasma producers
This article was originally published in Scrip
Mitsubishi Tanabe Pharma (MTP) has entered into discussions for the integration of its Benesis blood plasma derivatives subsidiary with the plasma fractionation operations of the Japanese Red Cross Society (JRC), in a move the two sides say will improve Japan's self-sufficiency in such products.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context